Trace Blood Elements and Severity of Parkinson’s Disease

Document Type : Original Article (s)

Authors

1 Assistant Professor, Department of Pharmacology, School of Medical Sciences, Islamic Azad University, Najafabad Branch AND Researcher, Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

2 Professor, Isfahan Neurosciences Research Center AND Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Isfahan Health Research Station, National Institute of Health Research, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Background: Parkinson's disease (PD) is a degenerative disorder of the nervous system and it seems that disturbances in trace elements homeostasis mediate progression of the disease. This study aimed to compare the levels of trace elements (Fe, Cu and Zn) in various stages of Parkinson's disease and to assess their correlation with the severity of the disease.Methods: Serum concentrations of trace elements were measured via Hitachi 902 biochemistry analysis in 109 patients with Parkinson's disease. Then, the severity of disease was evaluated and scored in four stages of 1-1.5, 2-2.5, 3, and 4-5 according to Hoehn and Yahr (HY) staging and also motor part of the Unified Parkinson’s Disease Rating Scale III (UPDRS III).Findings: All trace elements levels were within normal reference values and did not differ significantly between different Hoehn and Yahr stages (Fe: P = 0.670, Cu: P = 0.540, Zn: P = 0.340). Only patients with higher Hoehn and Yahr stages were older (P = 0.026). When the severity of Parkinson's disease was evaluated using UPDRS III, only there were significant association between age and the scale (P = 0.024).Conclusion: In this study, we confirmed only the age as a factor correlated with severity of Parkinson's disease. To clarify actual role of trace elements in this disease, more precise examination should be designed.

Keywords

References

  1. Ikawa M, Okazawa H, Kudo T, Kuriyama M, Fujibayashi Y, Yoneda M. Evaluation of striatal oxidative stress in patients with Parkinson's disease using [62Cu]ATSM PET. Nucl Med Biol 2011; 38(7): 945-51.
  2. Grabrucker AM, Rowan M, Garner CC. Brain-delivery of zinc-ions as potential treatment for neurological diseases: mini review. Drug Deliv Lett 2011; 1(1): 13-23.
  3. Wolozin B, Golts N. Iron and Parkinson's disease. Neuroscientist 2002; 8(1): 22-32.
  4. Younes-Mhenni S, Aissi M, Mokni N, Boughammoura-Bouatay A, Chebel S, Frih-Ayed M, et al. Serum copper, zinc and selenium levels in Tunisian patients with Parkinson's disease. Tunis Med 2013; 91(6): 402-5.
  5. Binolfi A, Rodriguez EE, Valensin D, D'Amelio N, Ippoliti E, Obal G, et al. Bioinorganic chemistry of Parkinson's disease: structural determinants for the copper-mediated amyloid formation of alpha-synuclein. Inorg Chem 2010; 49(22): 10668-79.
  6. Jimenez-Jimenez FJ, Fernandez-Calle P, Martinez-Vanaclocha M, Herrero E, Molina JA, Vazquez A, et al. Serum levels of zinc and copper in patients with Parkinson's disease. J Neurol Sci 1992; 112(1-2): 30-3.
  7. Kay AR, Toth K. Is zinc a neuromodulator? Sci Signal 2008; 1(19): re3.
  8. Kanninen KM, Grubman A, Meyerowitz J, Duncan C, Tan JL, Parker SJ, et al. Increased zinc and manganese in parallel with neurodegeneration, synaptic protein changes and activation of Akt/GSK3 signaling in ovine CLN6 neuronal ceroid lipofuscinosis. PLoS One 2013; 8(3): e58644.
  9. Mizuno D, Kawahara M. The molecular mechanisms of zinc neurotoxicity and the pathogenesis of vascular type senile dementia. Int J Mol Sci 2013; 14(11): 22067-81.
  10. Brewer GJ, Kanzer SH, Zimmerman EA, Molho ES, Celmins DF, Heckman SM, et al. Subclinical zinc deficiency in Alzheimer's disease and Parkinson's disease. Am J Alzheimers Dis Other Demen 2010; 25(7): 572-5.
  11. Forsleff L, Schauss AG, Bier ID, Stuart S. Evidence of functional zinc deficiency in Parkinson's disease. J Altern Complement Med 1999; 5(1): 57-64.
  12. Zhao HW, Lin J, Wang XB, Cheng X, Wang JY, Hu BL, et al. Assessing plasma levels of selenium, copper, iron and zinc in patients of Parkinson's disease. PLoS One 2013; 8(12): e83060.
  13. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 2001; 57(10): S11-S26.
  14. Goetz CG. Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS): a new scale for the evaluation of Parkinson's disease. Rev Neurol (Paris) 2010; 166(1): 1-4. [In French].
  15. Mariani S, Ventriglia M, Simonelli I, Donno S, Bucossi S, Vernieri F, et al. Fe and Cu do not differ in Parkinson's disease: a replication study plus meta-analysis. Neurobiol Aging 2013; 34(2): 632-3.
  16. Ahmed SS, Santosh W. Metallomic profiling and linkage map analysis of early Parkinson's disease: a new insight to aluminum marker for the possible diagnosis. PLoS One 2010; 5(6): e11252.
  17. Fukushima T, Tan X, Luo Y, Kanda H. Serum vitamins and heavy metals in blood and urine, and the correlations among them in Parkinson's disease patients in China. Neuroepidemiology 2011; 36(4): 240-4.
  18. Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991; 114 (Pt 4): 1953-75.
  19. Mann VM, Cooper JM, Daniel SE, Srai K, Jenner P, Marsden CD, et al. Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann Neurol 1994; 36(6): 876-81.
  20. Lotfipour AK, Wharton S, Schwarz ST, Gontu V, Schafer A, Peters AM, et al. High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson's disease. J Magn Reson Imaging 2012; 35(1): 48-55.
  21. Logroscino G, Marder K, Graziano J, Freyer G, Slavkovich V, LoIacono N, et al. Altered systemic iron metabolism in Parkinson's disease. Neurology 1997; 49(3): 714-7.
  22. Qureshi GA, Qureshi AA, Memon SA, Parvez SH. Impact of selenium, iron, copper and zinc in on/off Parkinson's patients on L-dopa therapy. J Neural Transm Suppl 2006; (71): 229-36.
  23. Ling H, Bhidayasiri R. Reduced serum caeruloplasmin levels in non-wilsonian movement disorders. Eur Neurol 2011; 66(3): 123-7.
  24. Hegde ML, Shanmugavelu P, Vengamma B, Rao TS, Menon RB, Rao RV, et al. Serum trace element levels and the complexity of inter-element relations in patients with Parkinson's disease. J Trace Elem Med Biol 2004; 18(2): 163-71.
  25. Pall HS, Williams AC, Blake DR, Lunec J, Gutteridge JM, Hall M, et al. Raised cerebrospinal-fluid copper concentration in Parkinson's disease. Lancet 1987; 2(8553): 238-41.
  26. Miao L, St Clair DK. Regulation of superoxide dismutase genes: implications in disease. Free Radic Biol Med 2009; 47(4): 344-56.
  27. Nikam S, Nikam P, Ahaley SK, Sontakke AV. Oxidative stress in Parkinson's disease. Indian J Clin Biochem 2009; 24(1): 98-101.
  28. Jimenez-Jimenez FJ, Molina JA, Aguilar MV, Meseguer I, Mateos-Vega CJ, Gonzalez-Munoz MJ, et al. Cerebrospinal fluid levels of transition metals in patients with Parkinson's disease. J Neural Transm 1998; 105(4-5): 497-505.
  29. Szyrwiel L, Pap JS, Malinka W, Szewczuk Z, Kotynia A, Brasun J. Interactions of anti-Parkinson drug benserazide with Zn(II), Cu(II), Fe(II) ions. J Pharm Biomed Anal 2013; 76: 36-43.
  30. Gellein K, Syversen T, Steinnes E, Nilsen TI, Dahl OP, Mitrovic S, et al. Trace elements in serum from patients with Parkinson's disease--a prospective case-control study: the Nord-Trondelag Health Study (HUNT). Brain Res 2008; 1219: 111-5.
Journal of Isfahan Medical School
Volume 32, Issue 308 - Serial Number 308
September and October 2015
Pages 1870-1878

Files

History

  • Receive Date: 13 September 2014
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics